Literature DB >> 15237931

Acromegalic cardiomyopathy: a review of the literature.

M P Matta1, P Caron.   

Abstract

Acromegaly is characterized by a high prevalence of cardiovascular complications that account for increased morbidity and mortality. Several studies emphasized the role of GH and IGF-1 excess in cardiac dysfunction. Coexisting factors such as hypertension, glucose tolerance abnormalities and coronary artery disease have a potential role in the progression of the acromegalic cardiomyopathy. Herein, we review the most relevant pathophysiological, functional and morphological findings in this specific disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15237931     DOI: 10.1023/b:pitu.0000023427.31609.a2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  73 in total

1.  Cardiac dysfunction in acromegaly: evidence by pulsed wave tissue Doppler imaging.

Authors:  G Mercuro; S Zoncu; P Colonna; P Cherchi; S Mariotti; F Pigliaru; L Petrini; S Iliceto
Journal:  Eur J Endocrinol       Date:  2000-09       Impact factor: 6.664

2.  Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.

Authors:  A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  Arrhythmia profile in acromegaly.

Authors:  G Kahaly; K V Olshausen; S Mohr-Kahaly; R Erbel; S Boor; J Beyer; J Meyer
Journal:  Eur Heart J       Date:  1992-01       Impact factor: 29.983

4.  Occurrence of ventricular late potentials in patients with active acromegaly.

Authors:  B L Herrmann; C Bruch; B Saller; S Ferdin; N Dagres; C Ose; R Erbel; K Mann
Journal:  Clin Endocrinol (Oxf)       Date:  2001-08       Impact factor: 3.478

5.  Fluorine-18 FDG myocardial positron emission tomographic findings before and after pituitary adenoma resection in a patient with acromegalic cardiomyopathy.

Authors:  N Tokita; S Hasegawa; M Hirata; J Yoshioka; H Yamaguchi; M Hori; T Nishimura
Journal:  Clin Nucl Med       Date:  2000-08       Impact factor: 7.794

6.  Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.

Authors:  A Sartorio; M Cattaneo; P Bucciarelli; B Bottasso; S Porretti; P Epaminonda; G Faglia; M Arosio
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

7.  Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly.

Authors:  Marie-Lise Jaffrain-Rea; Giuseppe Minniti; Carlo Moroni; Vincenzo Esposito; Elisabetta Ferretti; Antonio Santoro; Tommaso Infusino; Guido Tamburrano; Giampaolo Cantore; Rosario Cassone
Journal:  Eur J Endocrinol       Date:  2003-02       Impact factor: 6.664

8.  Cardiac physiology, biochemistry and morphology in response to excess growth hormone in the rat.

Authors:  S A Rubin; P Buttrick; A Malhotra; S Melmed; M C Fishbein
Journal:  J Mol Cell Cardiol       Date:  1990-04       Impact factor: 5.000

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Myxomatous degeneration and cystic medial necrosis associated with acromegaly.

Authors:  S M Ondreyco; H D Lewis; C R Hartman
Journal:  Arch Intern Med       Date:  1980-04
View more
  9 in total

Review 1.  Growth hormone and its disorders.

Authors:  J Ayuk; M C Sheppard
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

2.  Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy.

Authors:  Myung-Woo Hwang; Akira Shimatsu; Yoshio Sasaki; Hiroyuki Ayukawa; Katsura Inenaga; Rei Takeoka; Tomoyuki Iwase; Chuichi Kawai
Journal:  Heart Vessels       Date:  2007-05-21       Impact factor: 2.037

3.  Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues.

Authors:  A Comunello; F Dassie; C Martini; E De Carlo; R Mioni; M Battocchio; A Paoletta; F Fallo; R Vettor; P Maffei
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

4.  QT dispersion in patients with acromegaly.

Authors:  Mustafa Unubol; Ufuk Eryilmaz; Engin Guney; Mevlut Ture; Cagdas Akgullu
Journal:  Endocrine       Date:  2012-11-13       Impact factor: 3.633

5.  Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain.

Authors:  I C M Volschan; L Kasuki; C M S Silva; M L Alcantara; R M Saraiva; S S Xavier; M R Gadelha
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

Review 6.  Cardiovascular Disease in Acromegaly.

Authors:  Morali D Sharma; Anh V Nguyen; Spandana Brown; Richard J Robbins
Journal:  Methodist Debakey Cardiovasc J       Date:  2017 Apr-Jun

Review 7.  Clinical, quality of life, and economic value of acromegaly disease control.

Authors:  A Ben-Shlomo; M C Sheppard; J M Stephens; S Pulgar; S Melmed
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

8.  Normalization of plasma growth hormone alleviated malignant ventricular tachycardia in acromegaly.

Authors:  Zhi-Hao Liu; Kang Li; Yan-Sheng Ding; Jian-Xing Qiu; Steven Siyao Meng; Mohetaboer Momin; Sheng-Cong Liu; Tie-Ci Yi; Jian-Ping Li
Journal:  J Geriatr Cardiol       Date:  2018-08       Impact factor: 3.327

9.  Acromegaly: The Research and Practical Value of Noninvasive Hemodynamic Assessments via Impedance Cardiography.

Authors:  Agnieszka Jurek; Paweł Krzesiński; Grzegorz Gielerak; Przemysław Witek; Grzegorz Zieliński; Anna Kazimierczak; Robert Wierzbowski; Małgorzata Banak; Beata Uziębło-Życzkowska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-18       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.